Exposure of the tumor/immune cell co-cultures to the PD-1 blocking monoclonal antibody Pembrolizumab significantly enhanced the effector T-cell activation induced by proinflammatory cytokines and the concurrent blockade of PD-1 and IL-4Rα induced higher CD8+ T-cell activation. Here, CD8A is linked to neoplasm.